Although further work is warranted for a better understanding of mechanisms involved in disease dissemination and to elucidate the possible interactions of pathological TDP-43 with other AD-associated molecules, amyloid-β and tau, for patient stratification and development of novel therapeutic strategies, this last discovery support TDP-43 potential therapies as disease-modifying agents able to modulate the neurodegeneration. Here, MAPT is linked to Alzheimer disease.